1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 May 2024
Admin
News Article

Chugai Gets Japanese Approval for Foundationone Liquid CDx Cancer Genomic Profile

Chugai gets Japanese approval for FoundationOne Liquid CDx Cancer Genomic Profile to provide information on detection of copy number alterations of cancer-related genes and bTMB score

Overview

Chugai Pharmaceutical Co., Ltd. announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) on May 23, 2024, for FoundationOne Liquid CDx Cancer Genomic Profile to provide information on detection of copy number alterations of cancer-related genes and blood tumour mutational burden (bTMB) score. Copy number alterations and bTMB score in plasma samples are important indicators for predicting the efficacy of molecular target therapeutics such as immune checkpoint inhibitors. With this approval, our two comprehensive genomic profiling (CGP) tests using tissue and blood specimens, including FoundationOne CDx Cancer Genomic Profile, can support diagnosis and treatment decisions based on regulatory-approved information.

Words from CEO: Chugai

“We are pleased that two important additions that support cancer treatment decisions have been approved for FoundationOne Liquid CDx Cancer Genome Profile based on blood specimens in addition to the FoundationOne CDx cancer genomic profile using tissue specimens,” said Chugai’s president and CEO, Dr. Osamu Okuda.
“For patients with solid tumours for whom it is difficult to collect tissue samples, cancer genome profiling tests using blood specimens provide information on predicting the effectiveness of anticancer drug treatment, allowing for smooth consideration of treatment plans. We will continue our efforts to realize advanced personalized healthcare.”

About Chugai

As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized healthcare in oncology and contributing to patients through the expansion of CGP.

FoundationOne Liquid CDx Cancer Genomic Profile

Developed by Foundation Medicine Inc. based in Boston, USA, FoundationOne Liquid CDx Cancer Genomic Profile is a next-generation sequencing-based in vitro diagnostic device using blood samples for advanced cancer patients with solid tumours.
By using circulating tumour DNA (ctDNA) in the blood of patients with advanced solid tumours, it is intended to identify genomic alterations (base substitutions, insertions/deletions, rearrangements, copy numbers alterations) in 324 cancer-related genes and calculate the bTMB score.
It has been approved by the MHLW as a medical device program that has a genome profiling function for cancer-related genes and a companion diagnostic function for multiple molecular target drugs.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!